The expansion of the Hodgkin's lymphoma market around the world is anticipated to be driven by the approval of new medications for the treatment of Hodgkin's lymphoma by various regulatory authorities. Adcetris (brentuximab vedotin) can now be used in combination with AVD (adriamycin, vinblastine, and dacarbazine) chemotherapy to treat patients who have previously untreated Stage IV Hodgkin lymphoma (HL). This approval came from Health Canada in 2018, and it was granted to Seattle Genetics, Inc. as part of a supplemental New Drug Submission that the company had submitted. In adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), Adcetris is recommended for use in conjunction with doxorubicin, vinblastine, and dacarbazine as a therapy for classical Hodgkin lymphoma.
It is anticipated that regulatory authorities' propensity to approve new pharmaceuticals on a regular basis will have a favorable impact on the expansion of the global market for Hodgkin's lymphoma Treatment.
Leading Companies in the Hodgkin's Lymphoma Treatment Industry:
1 Emcure Pharmaceuticals Pvt. Ltd.
Emcure Pharmaceuticals Pvt. Ltd. was founded in 1981 and its headquarter Pune, Maharashtra, India.The company operates in 70 countries
2. Aspen Global Inc.
Aspen Global Inc. was founded in 2008, and it’s located Riviere du Rempart, Mauritius. The Company operates in 70 Countries.
